NasdaqCM - Delayed Quote USD

Salarius Pharmaceuticals, Inc. (SLRX)

0.4110 -0.0290 (-6.59%)
At close: June 7 at 4:00 PM EDT
0.3900 -0.02 (-5.11%)
Pre-Market: 5:00 AM EDT
Loading Chart for SLRX
DELL
  • Previous Close 0.4400
  • Open 0.4300
  • Bid --
  • Ask --
  • Day's Range 0.4110 - 0.4825
  • 52 Week Range 0.4110 - 1.8100
  • Volume 85,596
  • Avg. Volume 110,807
  • Market Cap (intraday) 1.963M
  • Beta (5Y Monthly) 0.97
  • PE Ratio (TTM) --
  • EPS (TTM) -2.0200
  • Earnings Date Aug 8, 2024 - Aug 12, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 3.25

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.

www.salariuspharma.com

2

Full Time Employees

December 31

Fiscal Year Ends

Recent News: SLRX

Performance Overview: SLRX

Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

SLRX
36.77%
S&P 500
12.10%

1-Year Return

SLRX
75.96%
S&P 500
24.82%

3-Year Return

SLRX
98.64%
S&P 500
26.41%

5-Year Return

SLRX
99.87%
S&P 500
88.04%

Compare To: SLRX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: SLRX

Valuation Measures

Annual
As of 6/7/2024
  • Market Cap

    1.96M

  • Enterprise Value

    -2.29M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    0.54

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -77.36%

  • Return on Equity (ttm)

    -193.68%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -8.92M

  • Diluted EPS (ttm)

    -2.0200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.37M

  • Total Debt/Equity (mrq)

    3.20%

  • Levered Free Cash Flow (ttm)

    -8.54M

Research Analysis: SLRX

Company Insights: SLRX

Research Reports: SLRX

People Also Watch